ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 94 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell Death Dis 2013 4, e801. ABT-737 purchased from Selleck.

    (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4K5SVI2OCCwTdMg MmT0O|IhcA>? MWjEUXNQ NIjCUoJk[XW|ZXSgPVcmKGyxc4Ogc4YhfmmjYnnsbZR6KGmwIHPlcIx{KHS{YX7z[oVkfGWmIIfpeIghSkOONjDzbXJPSQ>? MXeyOlY2PzJ6OB?=
KG1a MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGjLNlAxNTFyIN88US=> NVS0VVBbOjRiaB?= MnW4SG1UVw>? MYnJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NITpTHUzPjV3MkexNi=>
Kasumi-1 NUXoeo04S2WubDDWbYFjcWyrdImgRZN{[Xl? NIX1VHkxNTFyIN88US=> M1XpWFI1KGh? NVOycmF7TE2VTx?= MUjJR|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4HPdFI3PTV{N{Gy
KG1a MofrRZBweHSxc3nzJGF{e2G7 NYr2WYFvOC1zMDFOwG0> NW[1NmpJOjRiaB?= NGD4N2FFVVOR MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHuye4czPjV3MkexNi=>
Kasumi-1 MYnBdI9xfG:|aYOgRZN{[Xl? NYjQeIN3OC1zMDFOwG0> NX7nbo43OjRiaB?= NV;rS29lTE2VTx?= NWj1VlVJcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1rZOFI3PTV{N{Gy
MC-3  NWTiTYI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrmd3I2NzFyL{KwJO69VQ>? MmLUNlQhcA>? MYjEUXNQ M{i0fYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2jWU|I3PDR5NkG1
HN22  M3HpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPteXUzNjVxNz61M|IzNjVizszN M4XpW|I1KGh? MWTEUXNQ NWPxdWtmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX;VVlFMOjZ2NEe2NVU>
MC-3  M{X2SGFxd3C2b4Ppd{BCe3OjeR?= MXG1M|ExNzJyIN88US=> NEnUNoczPCCq MVfEUXNQ NUOwNmducW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> MXOyOlQ1PzZzNR?=
HN22  NWrhUpFzSXCxcITvd4l{KEG|c3H5 NF3pS|AzNjVxNz61M|IzNjVizszN NIe3XJgzPCCq NFPNbWxFVVOR NEDpZ29qdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz NHTRPFIzPjR2N{[xOS=>
MOLT-4 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHudXRqOTBvNUCwNEBvVQ>? NHS5NGM4OiCq NGC2e5VFVVOR Mom1TWM2OD1yLkG5PEDPxE1? MkS0NlY{QTJ|M{K=
RS4;11 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWxNE02ODByIH7N MlPvO|IhcA>? MmfDSG1UVw>? M4DoWGlEPTB;MD6wNFIh|ryP MV[yOlM6OjN|Mh?=
JURKAT M3;DNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCxNE02ODByIH7N M{frUlczKGh? NWHUNmlsTE2VTx?= M1P1b2lEPTB;Nk[g{txO MXeyOlM6OjN|Mh?=
CEM R M124Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj5d20yOC13MECwJI5O NGDKSWE4OiCq NGf4TVRFVVOR M1XGe2lEPTB;NT60JO69VQ>? NWnQNo1WOjZ|OUKzN|I>
CEM S MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDsbZhZOTBvNUCwNEBvVQ>? M3zMTlczKGh? M{T0TmROW09? M1i2WmlEPTB;MUKuNUDPxE1? M{jDdFI3Ozl{M{Oy
MOLT-4 M2DB[WFxd3C2b4Ppd{BCe3OjeR?= NFfY[FEyOC1zMECwJI5O NH\VcYIzPCCq NEfOV3pFVVOR M2LWbINifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x MYGyOlM6OjN|Mh?=
CEM S M2LtN2Fxd3C2b4Ppd{BCe3OjeR?= NGnWOYoyOC1zMECwJI5O NW[2NWN5OjRiaB?= NVLx[mtJTE2VTx?= M4L2NoNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x MlzNNlY{QTJ|M{K=
JURKAT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxNFAuOTByMDDuUS=> MWO0PEBp MmCxSG1UVw>? MoO0TWM2OD17NUZCtVkvOyCwTR?= NX2yb4tvOjZzN{KyOlk>
LOUCY NWH6b2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX6NVAxNTFyMECgcm0> M1PjU|Q5KGh? NXe1XXluTE2VTx?= NUfHclVOUUN3ME2zNk45yrFzMD65JI5O MoKxNlYyPzJ{Nkm=
WM-115 NEDhTZJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlvGNVAxyqCwTR?= NELxTmw4OiCq M3rTNYVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi M2faNFI3OTF4N{e2
B16 M4PKVmNmdGxiVnnhZoltcXS7IFHzd4F6 MVmxNFDDqG6P NH;5OGI4OiCq NFTRZWpmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= NXrCSFlqOjZzMU[3O|Y>
HL-60  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;DZVczKGh? NHrzN2RKSzVywrC9JFExNjdibl2= MorpNlYxPDV4MEm=
MOLM-13  MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\XXlczKGh? MV7JR|UxyqB;IEK3Mlkhdk1? MYOyOlA1PTZyOR?=
OCI-AML3 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzFV5g4OiCq NV;Qd4xoUUN3MNMgQUAyQTVyIH7N M2LtUVI3ODR3NkC5
BCWM.1 NUWzSpdtSXCxcITvd4l{KEG|c3H5 MWSwMVEvPiEQvF2= NXPuepU5OjRiaB?= NXfLblJ5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MWiyOVg6OzJ7MB?=
MWCL-1 NXLCeYplSXCxcITvd4l{KEG|c3H5 MYewMVEvPiEQvF2= MUSyOEBp M1nBc4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MmfkNlU5QTN{OUC=
MM.1s NEnYSZRCeG:ydH;zbZMhSXO|YYm= MV[wMVEvPiEQvF2= MYOyOEBp M3fSTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NVT6cFh7OjV6OUOyPVA>
HCT116 MnPKSpVv[3Srb36gRZN{[Xl? M1fHWlMwOTBizszN MWmxNuKhcMLi MkTuSG1UVw>? MUDpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25? NYrzUG8zOjV5MUWwNlg>
HCT116 BAX BAK1 DKO M1W3NmZ2dmO2aX;uJGF{e2G7 NVzVSVdqOy9zMDFOwG0> NGrse4oyOsLiaNMg M4\YPWROW09? M1rJfIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= MYOyOVcyPTB{OB?=
HCT116 MoL4SpVv[3Srb36gRZN{[Xl? MVuxNEDPxE1? M{HIOFEzyqCqwrC= M{H1eGROW09? M{e2eIlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= MVeyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO M3PYZmZ2dmO2aX;uJGF{e2G7 NY\1eJhwOTBizszN NGjYWIIyOsLiaNMg M{L2fGROW09? NU\uVpEzcW6lcnXhd4V{KEeIUD3MR|NDKHC3bnP0ZS=> MXOyOVcyPTB{OB?=
HCT116 M1u3VmF2fG:yaHHnfUBCe3OjeR?= MnLqNVAh|ryP M3yxN|EzyqCqwrC= M2r4W2ROW09? NEDwb|lqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? MXWyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO MmGyRZV1d3CqYXf5JGF{e2G7 NEDoWFYyOCEQvF2= NX\r[Yl2OTMEoHlCpC=> NY\CWlVsTE2VTx?= MWDpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NFPQepkzPTdzNUCyPC=>
U937 MUXBdI9xfG:|aYOgRZN{[Xl? Mo\UNE4yOjVvMjFOwG0> NESxNZYzPCCq MXrlcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?= NYXETopxOjV5MUSwNlQ>
U937  NYXyUoJ{SXCxcITvd4l{KEG|c3H5 NFPkWGExNjVizszN MnmwNlQhcA>? Ml\Y[Y5p[W6lZYOgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[U0{KGG|IIflcIwh[XNiTn;4ZUBt\X[nbB?= M2rZUlI2PzF2MEK0
HL-60 AAA-Bcl-2 M2DIV2Fxd3C2b4Ppd{BCe3OjeR?= NF7NSosxNTVizszN MoTVOFghcA>? MmPhTWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4W5[VI2PzFzNE[w
HL-60 EEE-Bcl-2 NEPQWnNCeG:ydH;zbZMhSXO|YYm= M4r5[VAuPSEQvF2= NGKxUG01QCCq M1fxfmlEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4jrc|I2PzFzNE[w
U87 M3rQbWZ2dmO2aX;uJGF{e2G7 MljGOVAh|ryP MoLNNlQhcA>? NXj6eGJ2emWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=> NX3zXZJrOjV4Nke2OlM>
K562 NYn0XGVCS2WubDDWbYFjcWyrdImgRZN{[Xl? NEm2UIkyNTFyIN88US=> MV[0PEBp Mn3iSG1UVw>? M{W3RmlEPTB;Mk[uO{DPxE1? NEXTPHYzPTV7NkW2NS=>
K562/Mcl -1-IRESBim MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTlwMzFOwG0> M{PZcFI2PTN3OUCw
K562/Bcl- 2-IRESBim M{HTRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DLfGlEPTB;MD6zOUDPxE1? NWLLbZFHOjV3M{W5NFA>
Jurkat NXjEdINjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TPT2lEPTB;MD62OkDPxE1? MVyyOVU{PTlyMB?=
JurkatΔBak M{\iW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRjVyIN88US=> NVL1U5RLOjV3M{W5NFA>
HL60/VCR MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\ZOGlEPTB-MUCwJO69VQ>? NHTJd|IzPTV|NUmwNC=>
Kasumi-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK5N4FtUUN3ME2wMlAyKM7:TR?= M3u5RlI2PTN3OUCw
Kasumi-1/ABT M2fZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPzSHJKSzVyPUCuOVEh|ryP NHzqWpQzPTV|NUmwNC=>
THP-1 M1LjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MortTWM2OD1zLkK3JO69VQ>? M{Hx[|I2PTN3OUCw
U937 M4HrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVwMkmg{txO M3\ONFI2PTN3OUCw
C1498 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LPbWlEPTB;Nj6xN{DPxE1? MWSyOVU{PTlyMB?=
RPMI 8226 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrDfY5KSzVyPUCuNlUh|ryP NYjqcmxwOjV3M{W5NFA>
MM.1S NVPBdYZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfufJRoUUN3ME2wMlQxKM7:TR?= MYmyOVU{PTlyMB?=
NCI-H929 M4XpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTwTWM2OD1zNT6yNUDPxE1? MnfoNlU2OzV7MEC=
U266 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DMVmlEPTB;MD62PEDPxE1? NH20e|UzPTV|NUmwNC=>
MCF-7 NVHPflZXS2WubDDWbYFjcWyrdImgRZN{[Xl? NXPLVW9EPSEQvF2= MkPSOFghcA>? NV;wOXRXTE2VTx?= MlLW[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>? M1;zV|I2PDB7MUK0
MCF-7 NGjhcHFCeG:ydH;zbZMhSXO|YYm= NVriUoszPSEQvF2= NYX5fGE{PC9{ND:0PEBp NFrkSmVFVVOR MmrhbY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC= NEDpe5czPTRyOUGyOC=>
MCF-7 MVvGeY5kfGmxbjDBd5NigQ>? NV7udWZPPSEQvF2= M1LYZlI1KGh? MYDEUXNQ NFPx[GRmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? Mn31NlU1ODlzMkS=
MDA-MB 231  NIX4[2FHfW6ldHnvckBCe3OjeR?= MWC1JO69VQ>? NEX4bJozPCCq NVXYfZY2TE2VTx?= M{HFboVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? MlLjNlU1ODlzMkS=
ZR-75-1  NGTyV2ZHfW6ldHnvckBCe3OjeR?= MU[1JO69VQ>? NX7lc4xMOjRiaB?= MUTEUXNQ MUXlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> NIryR5kzPTRyOUGyOC=>
A549 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX:wMVIxKM7:TR?= NH70Xno4OiCq MmKzSG1UVw>? NFW2dWll\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NX\qfppuOjV|OEi3OlI>
H1299 NYm5coplS2WubDDWbYFjcWyrdImgRZN{[Xl? NXG3OJBiOC1{MDFOwG0> MUC3NkBp NV25e3JOTE2VTx?= MWHk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv MkTMNlU{QDh5NkK=
HO-8910 NH32[|hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NInvRnYxNTJyIN88US=> NFLXdpI4OiCq MmTkSG1UVw>? NFq4TI5l\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw M{XQOlI2Ozh6N{[y
HT-29 Mn;0R4VtdCCYaXHibYxqfHliQYPzZZk> MUCwMVIxKM7:TR?= Ml73O|IhcA>? M3PhZ2ROW09? MkCx[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NX:wZ5Y1OjV|OEi3OlI>
HCT-116 NEXTXmVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVHJXJFnOC1{MDFOwG0> NITOPGg4OiCq MWPEUXNQ NFTOWVll\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NVWzb4ZCOjV|OEi3OlI>
A549 Mn:yRZBweHSxc3nzJGF{e2G7 NEf5eVEzOCEQvF2= M4TpOlQ5KGh? NGX3d45FVVOR NHW4V5pqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> M4i0fVI2Ozh6N{[y
H1299 MU\BdI9xfG:|aYOgRZN{[Xl? Mn70NlAh|ryP NWDJZ3o2PDhiaB?= NVWzOodzTE2VTx?= NIHETo5qdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> NV\HSppWOjV|OEi3OlI>
Sc-1 NXTzdXg2S2WubDDWbYFjcWyrdImgRZN{[Xl? NInkTYgxNjByMEGtNUDPxE1? MXy5OkBp M1LvboRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUnNNXdEOjV|N{O1NFg>
OcI-LY18 M2rMOGNmdGxiVnnhZoltcXS7IFHzd4F6 MYqwMlAxODFvMTFOwG0> M3TMUFk3KGh? NGTjXlNl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnvwNlU{PzN3MEi=
RL  NEXwOJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnnGNE4xODBzLUGg{txO MofDPVYhcA>? M2S1UoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NULiPHUzOjV|N{O1NFg>
RKO NGXXNVFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWfZVHFnOC1zMDFOwG0> NHmz[GczPOLCiXlCpC=> M1LSVGROW09? MlzGTWM2OD8kgJmyOgKBkcL3TR?= MmjKNlU{ODR|OEO=
Caco-2 MmPWR4VtdCCYaXHibYxqfHliQYPzZZk> NHXIU3AxNTFyIN88US=> Mni5NlTjiImqwrC= MU\EUXNQ NHnxdoNKSzVyPUG5MlfjiIoEtV2= M3OxdVI2OzB2M{iz
DLD1 NHjvPZBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M13YWlAuOTBizszN NV\aeW4zOjUkgJnoxsA> MnvZSG1UVw>? NF6wOVBKSzVyPUG4Mlc56oDLwsXN M2TxNFI2OzB2M{iz
LS411N M3zob2NmdGxiVnnhZoltcXS7IFHzd4F6 NX7DN3lIOC1zMDFOwG0> MoT0NlTjiImqwrC= Mk\mSG1UVw>? NHrvcGVKSzVyPUGxMlQ46oDLwsXN NGWw[2ozPTNyNEO4Ny=>
SW620 NF;NelVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M123TFAuOTBizszN MnT0NlTjiImqwrC= MnzUSG1UVw>? M{LVWGlEPTB;MUKuNlTjiIoEtV2= M3T2V|I2OzB2M{iz
HCT116 MoHmR4VtdCCYaXHibYxqfHliQYPzZZk> M2ruVlAuOTBizszN MYqyOQKBkWkEoB?= Mn65SG1UVw>? MYDJR|UxRTJyLkS55qCKyrWP MV6yOVMxPDN6Mx?=
HaCaT NH;sXHVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1;mRlAvOS9zL{GwJO69VQ>? MXKyOEBp NGPWVG9FVVOR MVnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX3B[3g6OjV{MUC3PVU>
A5-RT3 NIfZbo5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWPye5pjOC5zL{GvNVAh|ryP NILqNmQzPCCq NIHxVWtFVVOR NVrBOmJG\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NULKPVNuOjV{MUC3PVU>
HaCaT NV7aXpRRTnWwY4Tpc44hSXO|YYm= MlzRNVDjiIoQvF2= MXyyOE81QCCq NYf0V3FTTE2VTx?= MnrwbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w NYrFXYlPOjV{MUC3PVU>
A5-RT3 NWLkfY1vTnWwY4Tpc44hSXO|YYm= NIPJOJUyOOLCid88US=> NVuwc45iOjRxNEigbC=> MYLEUXNQ M1X3[Ylv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= NX;SSnlHOjV{MUC3PVU>
A5-RT3 MnrESpVv[3Srb36gRZN{[Xl? MnjWOUDPxE1? NFntdFE3KGh? NXW3NYk1TE2VTx?= NUjYPIw6cW6mdXPld{B1cGVicnXs[YF{\SCxZjDtbZRw[2ixbnTybYFtKHC{b4TlbY5{KGGwZDDy[YR2[2W|IHPsc45w\2WwaXOgd5Vzfmm4YXygbY4h[SClYYPwZZNmNWmwZHXw[Y5l\W62IH3hco5meg>? Mk\wNlUzOTB5OUW=
U266 NEDjSHFHfW6ldHnvckBCe3OjeR?= NVfTRYlsPTByL{e1NEBvVQ>? MlP5NlQwPDhiaB?= MV3EUXNQ NY\EVHYx\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju Mn:4NlUzODh6OEi=
RPMI8226 NXq5TGgyTnWwY4Tpc44hSXO|YYm= MX61NFAwPzVyIH7N M4noRlI1NzR6IHi= NXHzcHRPTE2VTx?= MmnY[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt MoTONlUzODh6OEi=
MM.1S MVPGeY5kfGmxbjDBd5NigQ>? MkHROVAxNzd3MDDuUS=> M{HTNVI1NzR6IHi= NWLQfnFLTE2VTx?= Mlzr[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt MVWyOVIxQDh6OB?=
Clone A NGeyWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTxNE4z6oDVNkCg{txO NXvrd3pJPzJiaB?= M2D4S2ROW09? MVHJR|UxRTdwNTFOwG0> M1zQPVI2OjB6OEiy
CX-1 Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nVeVAvOuLCk{[wJO69VQ>? NGTs[HI4OiCq NF:4SWhFVVOR MWTJR|UxRTFwODFOwG0> NV61Umh7OjV{MEi4PFI>
LS174T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nlZ|AvOuLCk{[wJO69VQ>? NFjwPWk4OiCq NXvQOGNkTE2VTx?= M1\abmlEPTB;MUiuN{DPxE1? NG\2T2wzPTJyOEi4Ni=>
HT29 MX7BdI9xfG:|aYOgRZN{[Xl? MkDKNU82NzFyIN88US=> Mm\EOFghcA>? M4LOZoNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlnYNlUyQTJzOEi=
SW480 MXPBdI9xfG:|aYOgRZN{[Xl? M160NlEwPS9zMDFOwG0> NWfRVphsPDhiaB?= NHKwSYhk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NH7PcpkzPTF7MkG4PC=>
Colo205 NFXndGJCeG:ydH;zbZMhSXO|YYm= MVWxM|UwOTBizszN NEPvSo01QCCq MYnjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXLXXmh4OjVzOUKxPFg>
Caco2 NXrJZ2xtSXCxcITvd4l{KEG|c3H5 MWOxM|UwOTBizszN NYfleIw6PDhiaB?= MYHjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHfOeFIzPTF7MkG4PC=>
PCI-13 NIfrR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fX[FczKGh? MmixSG1UVw>? NEPjcmFIUTVyPUG1JOKyKDFwODFOwG0> NWrYe2NwOjVzM{mzPFc>
PCI-15B MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rJVlczKGh? MXnEUXNQ NXruNFhDT0l3ME2xNUDDuSB2LkWg{txO M2\ESVI2OTN7M{i3
UM-SCC22B NXXrOYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp NID4c3ZFVVOR NWnWV|Z1T0l3ME2xPUDDuSB{Lkmg{txO NUXTWpBsOjVzM{mzPFc>
UM-SCC47 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\nbI04OiCq MkW5SG1UVw>? MYfHTVUxRTF7INMxJFEzNjNizszN NYXhSnpEOjVzM{mzPFc>
93-VU-147T NGj4T5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXGXWk4OiCq Ml\1SG1UVw>? NVftSXlyT0l3ME20MlMhyrFiMz61JO69VQ>? MlK1NlUyOzl|OEe=
UD-SCC2 NE\ReYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[3NkBp NVHx[|RXTE2VTx?= NYXodGpuT0l3ME2yPEDDuSB{Lkmg{txO M{TmR|I2OTN7M{i3
UPCI:SCC90 MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDYW5NsPzJiaB?= MWHEUXNQ NUjiVJNNT0l3ME22MlYhyrFiMT61JO69VQ>? M3XhZlI2OTN7M{i3
RPMI-8226  MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlLPNVI2NzJ3MD:1NFAhdk1? M4TT[FQ5cMLi NI[5V5dFVVOR MlTm[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnK2NlUxODh{MEK=
OPM-2  MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFLLSJkyOjVxMkWwM|UxOCCwTR?= M2XqNFQ5cMLi NWrHZpFLTE2VTx?= MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVjCZoh3OjVyMEiyNFI>
RPMI-8226  NGPW[IxCeG:ydH;zbZMhSXO|YYm= NH;0c4MyOjVxMkWwM|UxOCCwTR?= NXm2fmZCPDiqwrC= NUW5THN{TE2VTx?= MnWybY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGTwUlEzPTByOEKwNi=>
OPM-2  NGPRTmlCeG:ydH;zbZMhSXO|YYm= NU\aRWtIOTJ3L{K1NE82ODBibl2= MWC0PIjDqA>? M1PhVmROW09? MmrobY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWTVcoRyOjVyMEiyNFI>
COG-LL-319 MnXZSpVv[3Srb36gRZN{[Xl? NH3sTJIyODBibl2= MUGxM|MwPiCq M33Qc2ROW09? NEPFbXFqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen MXqyOFk2OTR5Mh?=
RS4;11 NFflV3RHfW6ldHnvckBCe3OjeR?= M1uwUFExOCCwTR?= NEjNe2syNzNxNjDo MYjEUXNQ M3;mZYlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V? MlzWNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID